Share：
Share this content in WeChat
X
[Chinese] [PDF] 5 1
• Reviews •
Research progress on the application of T1 mapping and T2 mapping technology in gynecological malignant tumors
ZHANG Xuxia  DENG Lin  ZHAI Xiaojing  SUN Bixia  CAO Shan  QIAN Jifang  ZHANG Shipeng  LIANG Li  ZHU Dalin 

Cite this article as: ZHANG X X, DENG L, ZHAI X J, et al. Research progress on the application of T1 mapping and T2 mapping technology in gynecological malignant tumors[J]. Chin J Magn Reson Imaging, 2026, 17(3): 206-212. DOI:10.12015/issn.1674-8034.2026.03.030.


[Abstract] In recent years, the incidence of gynecological malignant tumors has been progressively increasing with a tendency toward younger age at onset. Magnetic resonance imaging (MRI), boasting high soft tissue resolution, multi-sequence, and multi-planar imaging capabilities, has been extensively employed in the diagnosis, staging, and prognostic evaluation of gynecological tumors. However, conventional magnetic resonance sequences cannot accurately capture the early pathophysiological changes in tumor tissues. As a core technical combination in the field of functional MRI, T1 mapping and T2 mapping techniques utilize their respective core quantitative parameters (T1 values and T2 values) to precisely reflect microcosmic pathophysiological changes in lesion tissues (e.g., water molecule distribution, protein binding status, and tissue perfusion) from the perspectives of longitudinal and transverse relaxation properties of tissues, respectively. These parameters serve as pivotal imaging biomarkers for deciphering tumor pathological characteristics, assessing disease progression, and monitoring treatment response. This review systematically summarizes the latest research advances of T1 mapping and T2 mapping techniques, comprehensively analyzes their application values in the differential diagnosis, staging and grading, efficacy monitoring, and prognostic evaluation of common gynecological malignant tumors (including cervical cancer, endometrial carcinoma, and ovarian cancer), and discusses the current limitations in research (e.g., prolonged scanning time, inadequate standardization, and artifact interference). Furthermore, it proposes future optimization directions, aiming to more comprehensively unravel the pathophysiological mechanisms of gynecological malignant tumors and provide novel insights and approaches for precise diagnosis and treatment research in this field.
[Keywords] cervical cancer；endometrial carcinoma；ovarian cancer；magnetic resonance imaging；T1 mapping；T2 mapping

ZHANG Xuxia1   DENG Lin2   ZHAI Xiaojing1   SUN Bixia1   CAO Shan1   QIAN Jifang1   ZHANG Shipeng1   LIANG Li1   ZHU Dalin1*  

1 Medical Imaging Center of Gansu Provincial Maternity and Child-care Hospital, Lanzhou 730000

2 Prenatal Diagnosis Center of Gansu Provincial Maternity and Child-care Hospital, Lanzhou, 730000

Corresponding author: ZHU D L, E-mail: zdlldz@126.com

Conflicts of interest   None.

Received  2025-12-23
Accepted  2026-03-05
DOI: 10.12015/issn.1674-8034.2026.03.030
Cite this article as: ZHANG X X, DENG L, ZHAI X J, et al. Research progress on the application of T1 mapping and T2 mapping technology in gynecological malignant tumors[J]. Chin J Magn Reson Imaging, 2026, 17(3): 206-212. DOI:10.12015/issn.1674-8034.2026.03.030.

[1]
ZHU B H, GU H, MAO Z H, et al. Global burden of gynaecological cancers in 2022 and projections to 2050[J/OL]. J Glob Health, 2024, 14: 04155 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC11327849. DOI: 10.7189/jogh.14.04155.
[2]
KULKARNI A, SUN G, MANUPPELLI S, et al. Sexual health and function among patients receiving systemic therapy for primary gynecologic cancers[J]. Gynecol Oncol, 2022, 165(2): 323-329. DOI: 10.1016/j.ygyno.2022.03.008.
[3]
BOURGIOTI C, KONIDARI M, MOULOPOULOS L A. Manifestations of ovarian cancer in relation to other pelvic diseases by MRI[J/OL]. Cancers, 2023, 15(7): 2106 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC10093428. DOI: 10.3390/cancers15072106.
[4]
MAHESHWARI E, NOUGARET S, STEIN E B, et al. Update on MRI in evaluation and treatment of endometrial cancer[J]. Radiographics, 2022, 42(7): 2112-2130. DOI: 10.1148/rg.220070.
[5]
BONDE A, ANDREAZZA DAL LAGO E, FOSTER B, et al. Utility of the diffusion weighted sequence in gynecological imaging: review article[J/OL]. Cancers, 2022, 14(18): 4468 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC9496793. DOI: 10.3390/cancers14184468.
[6]
MESROPYAN N, HUAROC MOQUILLAZA E, CHANG J, et al. Dixon-based water T1 mapping for fat-corrected assessment of hepatic fibrosis in chronic liver disease[J]. Invest Radiol, 2026, 61(2): 84-91. DOI: 10.1097/RLI.0000000000001212.
[7]
DIEKMANN J, KOENIG T, THACKERAY J T, et al. Cardiac fibroblast activation in patients early after acute myocardial infarction: integration with MR tissue characterization and subsequent functional outcome[J]. J Nucl Med, 2022, 63(9): 1415-1423. DOI: 10.2967/jnumed.121.263555.
[8]
HASHIMOTO S, OHSAWA T, OMAE H, et al. Extracorporeal shockwave therapy for degenerative meniscal tears results in a decreased T2 relaxation time and pain relief: an exploratory randomized clinical trial[J]. Knee Surg Sports Traumatol Arthrosc, 2024, 32(12): 3141-3150. DOI: 10.1002/ksa.12384.
[9]
JIA T Y, QIN P X, HU F, et al. Principle of T1 mapping technique and its research progress in myocardial quantification[J]. Chin J Magn Reson Imaging, 2022, 13(3): 151-158. DOI: 10.12015/issn.1674-8034.2022.03.037.
[10]
JARKMAN C, CARLHÄLL C J, HENNINGSSON M. Clinical evaluation of the Multimapping technique for simultaneous myocardial T1 and T2 mapping[J/OL]. Front Cardiovasc Med, 2022, 9: 960403 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC9485633. DOI: 10.3389/fcvm.2022.960403.
[11]
MESSROGHLI D R, RADJENOVIC A, KOZERKE S, et al. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart[J]. Magn Reson Med, 2004, 52(1): 141-146. DOI: 10.1002/mrm.20110.
[12]
KALAPOS A, SZABÓ L, DOHY Z, et al. Automated T1 and T2 mapping segmentation on cardiovascular magnetic resonance imaging using deep learning[J/OL]. Front Cardiovasc Med, 2023, 10: 1147581 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC10374405. DOI: 10.3389/fcvm.2023.1147581.
[13]
GHAVAMIAN A, LIU C H, KANG B, et al. Liver T1 relaxation time of the 'normal liver' in healthy Asians: measurement with MOLLI and B1-corrected VFA methods at 3T[J/OL]. Br J Radiol, 2022, 95(1133): 20211008 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC10993984. DOI: 10.1259/bjr.20211008.
[14]
ZOU J, JIANG Y L, FAN F X, et al. The application of B1 inhomogeneity-corrected variable flip angle T1 mapping for assessing liver fibrosis[J/OL]. Magn Reson Imaging, 2024, 113: 110215 [2026-02-22]. https://www.sciencedirect.com/science/article/abs/pii/S0730725X24001905via%3Dihub. DOI: 10.1016/j.mri.2024.110215.
[15]
ZIBETTI M V W, MENON R G, DE MOURA H L, et al. Updates on compositional MRI mapping of the cartilage: emerging techniques and applications[J]. J Magn Reson Imaging, 2023, 58(1): 44-60. DOI: 10.1002/jmri.28689.
[16]
HANSON C A, KAMATH A, GOTTBRECHT M, et al. T2 relaxation times at cardiac MRI in healthy adults: A systematic review and meta-analysis[J]. Radiology, 2020, 297(2): 344-351. DOI: 10.1148/radiol.2020200989.
[17]
HUANG W P, WANG F, LIU H L, et al. A preliminary clinical application of T2 mapping-based radiomics on MRI in breast diseases[J]. Chin J Magn Reson Imaging, 2023, 14(2): 50-55. DOI: 10.12015/issn.1674-8034.2023.02.009.
[18]
KLINGEBIEL M, SCHIMMÖLLER L, WEILAND E, et al. Value of T2 mapping MRI for prostate cancer detection and classification[J]. J Magn Reson Imaging, 2022, 56(2): 413-422. DOI: 10.1002/jmri.28061.
[19]
BENCIKOVA D, HAN F, KANNENGIESER S, et al. Evaluation of a single-breath-hold radial turbo-spin-echo sequence for T2 mapping of the liver at 3T[J]. Eur Radiol, 2022, 32(5): 3388-3397. DOI: 10.1007/s00330-021-08439-y.
[20]
ZHU L H, LIU H, ZHOU J J. Research progress of magnetic resonance T2-mapping in body malignant tumors[J]. Chin J Magn Reson Imaging, 2020, 11(5): 398-400. DOI: 10.12015/issn.1674-8034.2020.05.019.
[21]
SHEN W, DAI G H, LIU F, et al. Research progress of magnetic resonance T2 mapping imaging in evaluating lumbar intervertebral disc degeneration[J]. Chin J Pain Med, 2022, 28(11): 854-859. DOI: 10.3969/j.issn.1006-9852.2022.11.010.
[22]
LIU J Z, ZHENG Z F, CHU Y J, et al. A novel biomarker for identifying HER2-low breast cancer using synthetic MRI[J/OL]. Sci Rep, 2026, 16: 1512 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC12796367. DOI: 10.1038/s41598-025-31322-5.
[23]
HUANG Z B, WANG L L, XU X Q, et al. Feasibility of using synthetic MRI to predict lymphatic vascular space invasion status in early-stage cervical cancer: added value to morphological MRI[J/OL]. Clin Radiol, 2024, 79(12): e1459-e1465 [2026-02-22]. https://www.sciencedirect.com/science/article/abs/pii/S0009926024004884. DOI: 10.1016/j.crad.2024.08.021.
[24]
PALMÉR M, ÅKESSON Å, LJUNGBERG M, et al. Preoperative risk assessment of endometrial cancer using histogram analysis of weighted and quantitative MRI images[J]. Abdom Radiol (NY), 2026, 51(1): 346-356. DOI: 10.1007/s00261-025-05069-6.
[25]
REZA S, ANJUM R, KHANDOKER R Z, et al. Public health concern-driven insights and response of low- and middle-income nations to the World health Organization call for cervical cancer risk eradication[J/OL]. Gynecol Oncol Rep, 2024, 54: 101460 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC11305207. DOI: 10.1016/j.gore.2024.101460.
[26]
XIAO M L, YAN B C, LI Y, et al. Diagnostic performance of MR imaging in evaluating prognostic factors in patients with cervical cancer: a meta-analysis[J]. Eur Radiol, 2020, 30(3): 1405-1418. DOI: 10.1007/s00330-019-06461-9.
[27]
VIVEROS-CARREÑO D, RODRIGUEZ J, RENDON PEREIRA G J, et al. Fertility-sparing surgery after neo-adjuvant chemotherapy in women with cervical cancer larger than 4 cm: a systematic review[J]. Int J Gynecol Cancer, 2022, 32(4): 486-493. DOI: 10.1136/ijgc-2021-003297.
[28]
LIU J, LI S J, LIU J J, et al. Application of T2 mapping quantitative imaging in assessing clinical stage and pathological differentiation of cervical cancer[J]. J Zhengzhou Univ Med Sci, 2023, 58(3): 419-423. DOI: 10.13705/j.issn.1671-6825.2022.06.062.
[29]
LI S J, CHENG J L, ZHANG Y, et al. Quantitative analysis of T2 mapping in evaluating pathological features of cervical cancer[J]. Chin J Med Imaging Technol, 2019, 35(9): 1365-1369. DOI: 10.13929/j.1003-3289.201903113.
[30]
SONG Q L, LIU A L, TIAN S F, et al. Texture analysis of pathological classification of cervical cancer and pathological grading of squamous cell carcinoma by T2 mapping imaging[J]. J China Clin Med Imaging, 2024, 35(6): 428-433. DOI: 10.12117/jccmi.2024.06.010.
[31]
ZHANG Z X, LIU J, ZHANG Y, et al. T1 mapping as a quantitative imaging biomarker for diagnosing cervical cancer: a comparison with diffusion kurtosis imaging[J/OL]. BMC Med Imaging, 2024, 24(1): 16 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC10782683. DOI: 10.1186/s12880-024-01191-x.
[32]
LI S J, LIU J, ZHANG W H, et al. T1 mapping and multimodel diffusion-weighted imaging in the assessment of cervical cancer: a preliminary study[J/OL]. Br J Radiol, 2023, 96(1148): 20220952 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC10392640. DOI: 10.1259/bjr.20220952.
[33]
XIE J, BAI J, SONG H Z, et al. Histologic features of cervical cancer by enhanced T1 mapping[J]. J Clin Radiol, 2023, 42(2): 291-295. DOI: 10.13437/j.cnki.jcr.2023.02.023.
[34]
YANG M, LI S J, LIU J, et al. Application value of T1 mapping imaging and diffusion kurtosis imaging in the evaluation of histological features of cervical cancer[J]. Henan Med Res, 2021, 30(6): 978-982. DOI: 10.3969/j.issn.1004-437X.2021.06.005.
[35]
ZHANG F F, GAO X M, CHENG J L, et al. Feasibility of quantitative T1-mapping reflecting histological features of cervical cancer: a primary study[J]. J Clin Radiol, 2020, 39(9): 1807-1811. DOI: 10.13437/j.cnki.jcr.2020.09.029.
[36]
LI S J, CHENG J L, ZHANG Y, et al. T1 mapping in evaluation of differentiation of cervical cancer: a primary study[J]. J China Clin Med Imaging, 2020, 31(4): 276-280. DOI: 10.12117/jccmi.2020.04.011.
[37]
LI M M, HA C C, XIE Y H, et al. Application of multimodal magnetic resonance ima1ging in the evaluation of pathological grading and staging of cervical cancer[J]. J Med Imaging, 2022, 32(9): 1551-1554. DOI: 10.20258/j.cnki.1006-9011.2022.09.021.
[38]
LIU J, LI S J, CAO Q C, et al. Prediction of recurrent cervical cancer in 2-year follow-up after treatment based on quantitative and qualitative magnetic resonance imaging parameters: A preliminary study[J]. Ann Surg Oncol, 2023, 30(9): 5577-5585. DOI: 10.1245/s10434-023-13756-1.
[39]
LIU J, LI S J, CAO Q C, et al. Risk factors for the recurrence of cervical cancer using MR-based T1 mapping: A pilot study[J/OL]. Front Oncol, 2023, 13: 1133709 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC10061013. DOI: 10.3389/fonc.2023.1133709.
[40]
GUO L M, WANG J, WU W Q, et al. A preliminary study of quantitative parameters derived from synthetic MRI for predicting the lymphovascular space invasion status in cervical squamous cell carcinoma[J]. Chin J Magn Reson Imaging, 2023, 14(11): 103-107, 120. DOI: 10.12015/issn.1674-8034.2023.11.017.
[41]
DONG L X, LIU J J, ZHANG Y J, et al. Prediction of lymphovascular space invasion in locally advanced cervical cancer patients after neoadjuvant chemotherapy based on pre-treatment multi-parameter MRI radiomics features[J]. Chin J Magn Reson Imaging, 2024, 15(8): 25-30, 45. DOI: 10.12015/issn.1674-8034.2024.08.004.
[42]
WANG Y, BAI J, SONG H Z, et al. Quantitative analysis of T2 mapping and T2* mapping in evaluating pathological features of cervical cancer[J]. J Clin Radiol, 2023, 42(5): 812-817. DOI: 10.13437/j.cnki.jcr.2023.05.032.
[43]
LI S J, LIU J, ZHANG F F, et al. Novel T2 mapping for evaluating cervical cancer features by providing quantitative T2 maps and synthetic morphologic images: a preliminary study[J]. J Magn Reson Imaging, 2020, 52(6): 1859-1869. DOI: 10.1002/jmri.27297.
[44]
LI S J, ZHANG Z X, LIU J, et al. The feasibility of a radial turbo-spin-echo T2 mapping for preoperative prediction of the histological grade and lymphovascular space invasion of cervical squamous cell carcinoma[J/OL]. Eur J Radiol, 2021, 139: 109684 [2026-02-22]. https://www.sciencedirect.com/science/article/abs/pii/S0720048X21001649. DOI: 10.1016/j.ejrad.2021.109684.
[45]
CAO J J, LI J, LI Q L, et al. Screening strategies for endometrial cancer[J]. Chin J Pract Gynecol Obstet, 2023, 39(11): 1062-1065. DOI: 10.19538/j.fk2023110102.
[46]
XU H. Application of MR T2mapping and MRS in aggressiveness of endometrial cancer[D]. Jinan: Shandong University, 2024. DOI: 10.27272/d.cnki.gshdu.2024.000540.
[47]
XU H, ZHANG J, HAN Y Q, et al. Role of T2 mapping of magnetic resonance imaging in the differentiation of endometrial cancer and benign endometrial lesions[J]. Diagn Interv Radiol, 2023, 29(1): 183-189. DOI: 10.4274/dir.2021.21884.
[48]
ZHU L H, LU W H, WANG F N, et al. Study of T2 mapping in quantifying and discriminating uterine lesions under different magnetic field strengths: 1.5 vsT. 3.0 T[J/OL]. BMC Med Imaging, 2023, 23(1): 1 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC9811773. DOI: 10.1186/s12880-022-00960-w.
[49]
LI S J, ZHANG Z X, LIU J, et al. The value of T2 mapping for evaluating the pathological type, grade and depth of myometrial invasion in endometrial carcinoma[J]. Chin J Oncol, 2023, 45(8): 673-680. DOI: 10.3760/cma.j.cn112152-20220124-00055.
[50]
TIAN S F, LIU A L, MENG X, et al. The value of amide proton transfer imaging and T2 mapping imaging technology in differentiation stage Ⅰ endometrial carcinoma and endometrial polyp[J]. J Clin Radiol, 2021, 40(9): 1832-1835. DOI: 10.13437/j.cnki.jcr.2021.09.036.
[51]
WANG M H, HUI P. A timely update of immunohistochemistry and molecular classification in the diagnosis and risk assessment of endometrial carcinomas[J]. Arch Pathol Lab Med, 2021, 145(11): 1367-1378. DOI: 10.5858/arpa.2021-0098-RA.
[52]
GUO Y E, LIU Y, ZHANG W, et al. The clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H/MMR-D endometrial carcinomas[J/OL]. Discov Oncol, 2022, 13(1): 12 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC8894509. DOI: 10.1007/s12672-022-00466-5.
[53]
CHUNG Y S, WOO H Y, LEE J Y, et al. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer[J/OL]. Am J Obstet Gynecol, 2021, 224(4): 370.e1-370.e13 [2026-02-22]. https://www.sciencedirect.com/science/article/abs/pii/S0002937820311753. DOI: 10.1016/j.ajog.2020.10.003.
[54]
RIEDINGER C J, ESNAKULA A, HAIGHT P J, et al. Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers[J]. Cancer, 2024, 130(3): 385-399. DOI: 10.1002/cncr.35030.
[55]
MIRZA M R, CHASE D M, SLOMOVITZ B M, et al. Dostarlimab for primary advanced or recurrent endometrial cancer[J]. N Engl J Med, 2023, 388(23): 2145-2158. DOI: 10.1056/nejmoa2216334.
[56]
MA C J, TIAN S F, CHEN L H, et al. Quantitative assessment of microsatellite instability in endometrial cancer by T2 mapping combined with m Dixon-Quant multiparameter imaging[J]. Chin J Magn Reson Imaging, 2022, 13(8): 48-54. DOI: 10.12015/issn.1674-8034.2022.08.009.
[57]
LIU X Y, YUAN Z L, YANG S Y, et al. Evaluating the utility of enhanced T1 mapping MR imaging in assessing depth of myometrial invasion and detecting DNA mismatch repair status in endometrial cancer: a pilot study[J/OL]. Abdom Radiol (NY), 2025 [2026-02-22]. https://link.springer.com/article/10.1007/s00261-025-05173-7. DOI: 10.1007/s00261-025-05173-7.
[58]
BEREK J S, MATIAS-GUIU X, CREUTZBERG C, et al. FIGO staging of endometrial cancer: 2023[J/OL]. J Gynecol Oncol, 2023, 34(5): e85 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC10482588. DOI: 10.3802/jgo.2023.34.e85.
[59]
MA C J, LIU A L, TIAN S F, et al. Preliminary study of APT combined with T2 mapping sequence in preoperative risk assessment of endometrial carcinoma[J]. Chin J Magn Reson Imaging, 2021, 12(9): 69-72. DOI: 10.12015/issn.1674-8034.2021.09.016.
[60]
ZHANG Z X, LIU J, WANG W J, et al. Feasibility of accelerated T2 mapping for the preoperative assessment of endometrial carcinoma[J/OL]. Front Oncol, 2023, 13: 1117148 [2026-02-22]. https://pmc.ncbi.nlm.nih.gov/articles/PMC10411727. DOI: 10.3389/fonc.2023.1117148.
[61]
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[62]
YANG X Y, CHEN D Y, WANG H X, et al. Analysis of prevalence, trends and prediction of ovarian cancer among women in China[J]. J Chongqing Med Univ, 2022, 47(9): 1030-1035. DOI: 10.13406/j.cnki.cyxb.003104.
[63]
CARTER J S, KOOPMEINERS J S, KUEHN-HAJDER J E, et al. Quantitative multiparametric MRI of ovarian cancer[J]. J Magn Reson Imaging, 2013, 38(6): 1501-1509. DOI: 10.1002/jmri.24119.
[64]
ABE T, SAIDA T, YOSHIDA M, et al. Prognostic imaging features of ovarian clear cell carcinoma on multiparametric MRI[J/OL]. Abdom Radiol (NY), 2025 [2026-02-22]. https://link.springer.com/article/10.1007/s00261-025-05272-5. DOI: 10.1007/s00261-025-05272-5.
[65]
SONG X L, REN J L, YAO T Y, et al. Radiomics based on multisequence magnetic resonance imaging for the preoperative prediction of peritoneal metastasis in ovarian cancer[J]. Eur Radiol, 2021, 31(11): 8438-8446. DOI: 10.1007/s00330-021-08004-7.

PREV Research progress of magnetic resonance imaging combined with artificial intelligence in the precision diagnosis and treatment of cervical cancer
NEXT Research progress of deep learning combined with radiomics in musculoskeletal diseases
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn